Aspire Pharmaceuticals, Inc.
FDA warning letter issued 2022-11-22 · posted 2023-04-04
Letter details
- Company
- Aspire Pharmaceuticals, Inc.
- Subject
- CGMP/Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements/Adulterated
- Issuing office
- Division of Human and Animal Food Operations East II
- Letter issue date
- 2022-11-22
- Posted date
- 2023-04-04
- Case number
- 630328
Read the full letter on fda.gov
FDA's public listing keeps roughly five years of letters; older ones roll off. Atlas preserves every letter it has ingested since September 2026 and refreshes the listing weekly. Verify enforcement matters against the primary source linked above.
Hear about the next one
Watch an issuing office from its directory page and new letters land in your change alerts. Elsewhere this data sells for hundreds of dollars per document; here it is part of the record.